Skip to content

A study comparing two creams, cysteamine and hydroquinone, for the treatment of melasma (facial dark patches)

Efficacy and Tolerability of Topical 5% Cysteamine and Topical 2% Hydroquinone for the Treatment of Melasma: A Randomized Comparative Investigator-Blind Clinical Study - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107911
Enrollment
60
Registered
2026-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Topical cream comparison: A total of 60 patients clinically diagnosed with melasma will be recruited from the Dermatology Outpatient Department of Krishna Hospital, Karad. Eligible pati

Sponsors

Krishna Vishwa Vidyapeeth (Deemed to be University)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: To enrol the patient in the study, the patient must- Have given written consent before any treatment is commenced. Adults aged 18 50 years. Fitzpatrick skin types III V (explained below). No use of depigmenting agents, chemical peels, or laser therapy in the past 3 months.

Exclusion criteria

Exclusion criteria: Exclusion criteria- The following patients will be excluded from the study- Pregnant/lactating women. Allergy to cysteamine or hydroquinone. Active dermatological conditions affecting study results. Patients with unrealistic expectations about the outcome of treatment

Design outcomes

Primary

MeasureTime frame
Primary Outcome Change in MASI score from baseline to 12 weeks. Dermoscopic development through the course of the visits Timepoint: Outcomes measured at 4 weeks, 8 weeks and 12 weeks

Secondary

MeasureTime frame
Secondary Outcomes Physician s Global Assessment (PGA) score. Patient satisfaction score (PSS) using a 5-point Likert Scale. Occurrence of adverse effects. Timepoint: At 12 weeks For adverse effects, anytime in the study

Countries

India

Contacts

Public ContactVarsha Jamale

Krishna Vishwa Vidyapeeth (Deemed to be University),Karad

arundati99@gmail.com9930746769

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026